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Abstract
Background

Clinical reports suggest that rather than directly driving cocaine use, stress may create a biological context
within which other triggers for drug use become more potent. We hypothesize that stress-induced increases
in corticosterone“set the stage” for relapse by promoting endocannabinoid-induced attenuation of inhibitory
transmission in the prelimbic cortex (PL).

Methods

We have established a rat model for these stage-setting effects of stress. In this model, neither a stressor
(electric footshock) nor stress-level corticosterone treatment alone reinstates cocaine seeking following selfadministration and extinction, but each treatment potentiates reinstatement in response to an otherwise
subthreshold cocaine priming dose (2.5 mg/kg, intraperitoneal). The contributions of endocannabinoid signaling
in the PL to the effects of stress-level corticosterone on PL neurotransmission and cocaine seeking were
determined using intra-PL microinfusions. Endocannabinoid-dependent effects of corticosterone on
inhibitory synaptic transmission in the rat PL were determined using whole-cell recordings in layer V pyramidal
neurons.

Results

Corticosterone application attenuated inhibitory synaptic transmission in the PL via cannabinoid receptor type 1
(CB1R)– and 2-arachidonoylglycerol–dependent inhibition of gamma-aminobutyric acid release without altering
postsynaptic responses. The ability of systemic stress-level corticosterone treatment to potentiate cocaineprimed reinstatement was recapitulated by intra-PL injection of corticosterone, the CB1R agonist WIN 55,212-2,
or the monoacylglycerol lipase inhibitor URB602. Corticosterone effects on reinstatement were attenuated by
intra-PL injections of either the CB1R antagonist, AM251, or the diacylglycerol lipase inhibitor, DO34.

Conclusions

These findings suggest that stress-induced increases in corticosterone promote cocaine seeking by mobilizing 2arachidonoylglycerol in the PL, resulting in CB1R-mediated attenuation of inhibitory transmission in this brain
region.
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Despite efforts to identify effective treatment strategies for patients with substance use disorders (SUDs),
relapse rates remain high. This prevalence is due in part to the complex interactions among factors that promote
drug craving and seeking. One factor, stress, is particularly problematic, as it is prevalent in SUD populations and
unavoidable in daily life. Although there is a well-demonstrated influence of stress on drug craving in individuals
with SUDs 1, 2, the effects of stress on drug-seeking behavior can be complex. Emerging evidence indicates that
stress does not always directly trigger craving but instead can increase reactivity to other relapse-inducing
stimuli 3, 4, 5, 6. This understudied influence of stress can also be observed in rats 7, 8, 9, 10. While it has been
established that both stress (11) and high-dose priming injections of the drug (12) can trigger reinstatement,
under conditions in which stress does not directly trigger reinstatement it can potentiate cocaine seeking in
response to an otherwise subthreshold priming injection of cocaine following self-administration and
extinction 8, 10.
Footshock-induced potentiation of cocaine seeking is glucocorticoiddependent,
and corticosterone administration at a dose that reproduces stress-induced levels is sufficient to potentiate
reinstatement (8). A likely site of corticosterone regulation of cocaine use is the medial prefrontal cortex. The
prelimbic region of the medial prefrontal cortex has been extensively implicated in cocaine-seeking
behavior 13, 14, 15 and is highly regulated by stress and glucocorticoids 16, 17. Taken together, these data
provide strong evidence that the prefrontal cortex is a key site for corticosterone actions that mediate stress
regulation of cocaine-seeking behavior.
Corticosterone may regulate prefrontal cortical function through interactions with the endocannabinoid system.
In the prefrontal cortex, cannabinoid receptor type 1 (CB1R) is predominantly located on perisomatically
targeting gamma-aminobutyric acidergic (GABAergic) interneurons (18), positioning activation of this system to
regulate output of prefrontal pyramidal neurons. In mice, stress can increase levels of the endocannabinoid 2arachidonoylglycerol(2-AG) in the prefrontal cortex in a glucocorticoid-dependent manner (18). Furthermore,
bath application of corticosterone to mouse prefrontal slices attenuates inhibitory neurotransmission in a CB1Rdependent manner (18). Importantly, the same stressor, electric footshock, which potentiates reinstatement of
cocaine seeking, also elevates levels of endocannabinoids in subregions of the prefrontal cortex in drug-naïve
rats (10). Taken together, these data suggest that stress, and corticosterone, potentiate reinstatement through
increased CB1R activation in the prelimbic cortex (PL). Importantly, we and others have demonstrated that
systemic CB1R antagonism blocks stress-potentiated but not stress-induced 19, 20 or cocaineinduced 10, 20reinstatement.
In the current study, we test the hypothesis that in rats, corticosterone exerts effects in the prelimbic subregion
of the medial prefrontal cortex to potentiate reinstatement of cocaine seeking through a CB1R-dependent
attenuation of inhibitory neurotransmission. We demonstrate that corticosterone acts in the PL to potentiate
cocaine seeking, and that corticosterone attenuates inhibitory neurotransmission in PL slices in a CB1Rdependent manner. Furthermore, we show that CB1R activation in the PL is necessary for stress- and
corticosterone-potentiated reinstatement as well as sufficient to reproduce the potentiating effects of stress or
corticosterone administration. Finally, we determine that PL CB1R activation involves 2-AG signaling, as
inhibition of 2-AG production blocks and attenuation of 2-AG breakdown reproduces corticosterone-potentiated
reinstatement.

Methods and Materials
Subjects

A total of 102 male Sprague Dawley rats (275 to 300 g at arrival; Envigo RMS, Inc., Indianapolis, IN), were
individually housed in a 12-hour reverse light/dark cycle (7 am to 7 pm lights off) as described in
the Supplement. All behavioral procedures were conducted in the dark phase. Of the rats designated
for behavioral testing, 14 were excluded from the study because of misplaced cannulation or because they did
not complete all behavioral testing.

Surgery

For intravenous self-administration and reinstatement testing, rats were anesthetized with ketamine HCl (100
mg/kg, intraperitoneal [i.p.]; Henry Schein, Melville, NY) and xylazine (2 mg/kg, i.p.; Henry Schein) and surgically
implanted with indwelling venous catheters. Rats that received intracranial microinfusions before reinstatement
testing also had a bilateral guide cannulatargeting the PL. All procedures are described in detail in
the Supplement.

Cocaine Self-administration, Extinction, and Reinstatement

Rats were trained to press a lever to self-administer cocaine (0.5 mg/kg/infusion) under a fixed-ratio 4 schedule
of reinforcement during daily 2-hour sessions. Once trained, rats underwent daily self-administration for 14 days
before extinction training, during which the cocaine solution was replaced with saline. Each rat underwent
extinction training until extinction criterion was met (<10 lever presses/2 hours) at which point reinstatement
testing was conducted. Procedures are described in detail in the Supplement.

Reinstatement Conditions

The 2-hour reinstatement sessions were preceded by footshock, corticosteroneadministration, and/or drug
delivery, as described in the Results, and were otherwise identical to extinction conditions. A within-subject
testing design was utilized in which each rat received all treatments in a given experiment in a counterbalanced
order. Nine rats did not complete all tests and were excluded from the study. Reinstatement was defined as
significantly increased responding on the lever previously reinforced by cocaine relative to the preceding
extinction session and compared with control conditions. Responding on a second lever that was inactive
through self-administration training was also recorded during the sessions. There were no significant changes in
inactive lever responding between extinction and reinstatement testing days (Supplemental Figure S3).
Potentiated cocaine seeking was defined as significant reinstatement in response to low-dose cocaine (2.5
mg/kg, i.p.) following shock or drug pretreatment under conditions where neither low-dose cocaine nor the drug
pretreatment alone produced reinstatement.

Intracranial Drug Administration

Intra-PL infusions were given at various time points before reinstatement testing as described in the Results. All
infusions were a volume of 0.3 μL at a rate of 0.3 μL/min. Placement of the guide cannula was verified as
described in the Supplement. Albeit in only 5 rats, injections outside of the PL did not have effects on cocaineseeking behavior.

Slice Electrophysiology

Whole-cell voltage clamp recordings were made from pyramidal neurons in layer V of the PL of drug-naïve rats
as described in detail in the Supplement. For recording of evoked inhibitory postsynaptic currents (IPSCs), layer
V pyramidal neurons were voltage-clamped at −60 mV, and IPSCs were evoked at 0.05 Hz by
a tungsten stimulation electrode placed near the apical dendrites. Spontaneous miniature IPSCs (mIPSCs) were
recorded from the pyramidal neurons at a holding potential of −70 mV. Action potential generation was blocked

with tetrodotoxin (0.5 μM). Glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (10 μM) and
D-2-amino-5-phosphonovaleric acid (20 μM) were present in the artificial cerebrospinal fluid throughout the
experiments. Series resistance (15 to 30 MΩ) was monitored throughout the recordings, and data were
discarded if the resistance changed by more than 20%. All recordings were performed at 32 ± 1°C.

Mass Spectrometry

To determine if the diacylglycerol lipase (DAGL) inhibitor DO34 attenuates corticosterone-induced 2-AG levels,
rats received intra-PL infusions of DO34 (1 μg/0.3 μL) or vehicle (70% dimethyl sulfoxide) 30 minutes before a
corticosterone (2 mg/kg, i.p.) or vehicle (10% ethanol) injection. Rats were rapidly decapitated 45 minutes
following the injection and brains were removed within 90 seconds, frozen in liquid nitrogen, and stored
at −80°C. The PL was dissected and endocannabinoids extracted as previously described (10). Narachidonoylethanolamine and 2-AG were isolated and quantified as described in
the Supplement using isotope dilution and liquid chromatography/mass spectrometry.

Statistical Analysis

Statistical analyses were conducted using one- or two-way repeated-measures (RM) analysis of variance
(ANOVA), followed by Bonferroni post hoc tests when appropriate for behavioral and mass
spectrometry experiments and Student’s ttest for electrophysiology experiments (see the Supplement for more
detail).

Results
Corticosterone Acts in the PL to Potentiate Reinstatement

After 14 days of stable cocaine self-administration, responding was extinguished and rats were tested for
reinstatement of cocaine seeking. All self-administration and extinction data are displayed in Supplemental
Table S1. As previously reported under these conditions 8, 10, electric footshock stress (3 × 0.5 mA, 200-ms
duration, mean intershock interval 40 seconds, range 10 to 70 seconds over a 15-minute period) alone did not
induce reinstatement, but rather potentiated cocaine seeking in response to an otherwise subthreshold priming
dose of cocaine (2.5 mg/kg, i.p.; Figure 1A; two-way RM ANOVA, reinstatement condition × day interaction
[F3,15 = 17.11, p < .001], post hoc comparison, shock/cocaine combination vs. extinction, p < .05). The ability of
footshock to potentiate reinstatement was reproduced by systemic administration of corticosterone (2 mg/kg,
i.p.) at a dose that established footshock-induced levels of plasma corticosterone (Supplemental Figure S1). As
with footshock, corticosterone alone was insufficient to induce reinstatement. However, when corticosterone
was combined with an otherwise subthreshold priming injection of cocaine, significant reinstatement was
observed (Figure 1B; two-way RM ANOVA, reinstatement condition × day [F3,12 = 10.30, p < .001], post hoc
comparison, corticosterone/cocaine combination vs. extinction, p < .05). To localize corticosterone action in the
brain, soluble 2-hydroxypropyl-β-cyclodextrin–conjugated corticosterone (50 ng/0.3 μL), was microinfused
directly into the PL 10 minutes before low-dose cocaine. As was the case with systemic administration, intra-PL
administration of corticosterone alone did not increase cocaine seeking, but rather induced significant
reinstatement when given before administration of the subthreshold priming dose of cocaine (Figure 1C; twoway RM ANOVA, reinstatement condition × day interaction [F2,12 = 4.89, p < .05], post hoc comparison,
corticosterone/cocaine combination vs. extinction, p < .05). These findings identify the PL as an important site
for corticosterone effects on cocaine seeking.

Figure 1. Corticosterone (CORT) acts in the prelimbic cortex to potentiate reinstatement of cocaine (COC)
seeking. (A) Electric footshock stress (SHOCK) (n = 6) potentiates reinstatement when given in combination with a low
dose of cocaine (COC) (2.5 mg/kg, intraperitoneal [i.p.]). (B) Systemic corticosterone (2 mg/kg, i.p.; n = 5) reproduces the
effect of footshock and potentiates reinstatement when given 40 minutes before an injection of low-dose cocaine (2.5
mg/kg, i.p.). (C) 2-Hydroxypropyl-β-cyclodextrin (HBC)–conjugated corticosterone (50 ng/0.3 μL; n = 7) administered directly
into the prelimbic cortex (PL) 10 minutes before a low-dose cocaine injection (2.5 mg/kg, i.p.) induces significant
reinstatement whereas either administered alone does not (p < .05; **p < .01, *p < .05, compared with
extinction). (D) Injection needle tips of all rats included in the intra-PL corticosterone experiment. Data are presented as
mean ± SEM.

Corticosterone Attenuates PL Inhibitory Neurotransmission in a CB1R-Dependent
Manner

To investigate corticosterone effects on PL neurotransmission in rats, whole-cell recordings were made in
visually identified layer V pyramidal neurons in rat PL. We initially examined the effects of corticosterone on
evoked IPSCs. Following stable baseline recordings, bath application of corticosterone (1 μM) for 30 minutes
gradually decreased the amplitude of evoked IPSCs with the depression having a rapid onset (∼5 minutes) and
peaking in 30 minutes (Figure 2A). This depression was accompanied by an increase in the paired-pulse ratio,
suggesting a presynaptic mechanism (Figure 2B). The depression of evoked IPSC amplitude by corticosterone
was prevented by the continuous presence of CB1R antagonist AM251 (2 μM; Figure 2A). Moreover, in the
presence of AM251, paired-pulse ratio was not altered by corticosterone (Figure 2B). Thus, these results suggest
that corticosterone depresses IPSCs in rat PL through a presynaptic CB1R-dependent mechanism. To further test
this, we examined the effects of corticosterone on mIPSCs in layer V pyramidal neurons in rat PL slices. A change
in mIPSC frequency indicates a presynaptic mechanism, whereas a change in mIPSC amplitude signifies a likely
change in postsynaptic responsiveness (21). PL slices were perfused with either vehicle or corticosterone (1 μM)
for 20 to 60 minutes, and mIPSCs were recorded from layer V pyramidal neurons. Corticosterone perfusion
significantly decreased the frequency of mIPSCs (Figure 2D) as shown by both a decrease in the mean frequency
of mIPSCs (p < .01) and a rightward shift in the cumulative probability plot for interevent intervals. By contrast,
corticosterone did not alter the mean amplitude of mIPSCs (Figure 2E; p > .05) or the cumulative amplitude
distribution (p > .05). To investigate if corticosterone depressed mIPSCs through a CB1R-dependent mechanism,
we repeated the above experiments in the presence of the CB1R antagonist AM251. PL slices were perfused with
either AM251 (2 μM) alone or AM251 with corticosterone (1 μM) for 20 to 60 minutes. In the presence of
AM251, corticosterone did not significantly alter mIPSCs (Figure 2D; p > 05) as there were no significant changes
in the mean frequency of mIPSCs (p > .05) or the cumulative interevent interval probability plot (p >.05). In the
presence of AM251, corticosterone did not significantly alter the mean amplitude of mIPSCs (Figure 2E; p > .05)
or cumulative amplitude distribution (p > .05). These results suggest that corticosterone-induced depression of
mIPSCs in the PL is dependent on presynaptic CB1R-mediated suppression of GABAergic transmission.

Figure 2. Corticosterone (Cort) depressed evoked and miniature inhibitory postsynaptic currents (mIPSCs) through
a cannabinoid receptor type 1 (CB1R)–dependent mechanism in rat prelimbic cortex (PL) slices. (A) Bath application of
corticosterone (1 μM) caused rapid depression of evoked IPSCs (n = 10 neurons; n = 2-3 rats) in layer V pyramidal neurons in
the prelimbic cortex (PL), which were blocked by the CB1R antagonist AM251 (2 μM, n = 11 neurons; n = 2–3 rats). (B) Bath
application of corticosterone increased the paired-pulse ratio, which was blocked by AM251 (n = 11 neurons; n = 2–3 rats, p
< .05). (C) Representative traces of mIPSCs recorded in layer V pyramidal neurons in PL slices that were treated with vehicle
(control), corticosterone (1 μM), AM251 (2 μM), or AM251 plus corticosterone (1 μM). (D) Corticosterone treatment

decreased the mean frequency of mIPSCs (n = 9–11 neurons; n = 2–3 rats, p < .01) and caused a right shift of the interevent
intervals of the cumulative probability plot. However, in the presence of AM251, corticosterone did not alter the mean
frequency of mIPSCs (n = 10–11 neurons; n = 2–3 rats, p > .05) or interevent intervals of the cumulative probability
plot. (E) Corticosterone did not alter the mean amplitude of mIPSCs (p > .05) and cumulative amplitude distribution. In
addition, in the presence of AM251, corticosterone had no significant effect on the mean amplitude of mIPSCs (p > .05) or
on the cumulative amplitude distribution of mIPSCs.

CB1R Activation in the PL Is Necessary and Sufficient for Stress- and CorticosteronePotentiated Reinstatement

We have previously shown that stress-potentiated reinstatement is prevented by systemic administration of the
CB1R antagonist, AM251 (10). These data, in combination with the observed CB1R-dependent corticosterone
attenuation of PL inhibitory neurotransmission, led us to hypothesize that stress-potentiated reinstatement is
mediated by corticosterone-regulated endocannabinoidsignaling and PL CB1R activation. Consistent with this
possibility, intra-PL administration of AM251 (300 ng/0.3 μL) 15 minutes before footshock blocked stresspotentiated reinstatement (Figure 3A; two-way RM ANOVA, reinstatement condition × day interaction [F3,15 =
15.71, p < .001]; post hoc comparison, vehicle/shock/cocaine combination vs. extinction, p < .05;
AM251/shock/cocaine combination vs. extinction, p > .05). Moreover, intra-PL administration of AM251 (300
ng/0.3 μL) 15 minutes before systemic corticosterone administration (2 mg/kg, i.p.) also blocked corticosteronepotentiated reinstatement (Figure 3B; two-way RM ANOVA, reinstatement condition × day interaction [F3,15 =
6.94, p < .01], post hoc comparison, vehicle/corticosterone/cocaine combination vs. extinction, p < .05;
AM251/corticosterone/cocaine combination vs. extinction, p > .05). These data provide compelling evidence
that stress, likely through corticosterone, promotes cocaine seeking via increased endocannabinoid signaling in
the PL. To determine if CB1R activation in the PL is sufficient to potentiate cocaine-primed reinstatement, we
tested rats for the effects of the intra-PL delivery of the CB1R agonist WIN 55,212-2 on reinstatement. Neither
intra-PL WIN 55,212-2 (50 ng/0.3 μL; 15-minute pretreatment) nor 2.5 mg/kg (i.p.) cocaine alone increased
cocaine seeking. However, when intra-PL WIN 55,212-2 preceded the cocaine injection, significant
reinstatement was observed (Figure 4A; two-way RM ANOVA, reinstatement condition × day interaction [F2,10 =
7.09, p < .05], post hoc comparison WIN/cocaine combination vs. extinction, p < .05).

Figure 3. Stress- and corticosterone-potentiated reinstatement is blocked by cannabinoid receptor type 1 (CB1R)
antagonism in the prelimbic cortex (PL). (A)Electric footshock stress (SHOCK)–potentiated reinstatement to lowdosecocaine (COC) (2.5 mg/kg, intraperitoneal [i.p.]) is blocked by pretreatment with an intra-PL infusion of the CB1R
antagonist AM251 (300 ng/0.3 μL) 15 minutes before the reinstatement test (n = 6, *p < .05, compared with
extinction). (B)Corticosterone (CORT) (2 mg/kg, i.p.)–potentiated reinstatement to low-dose cocaine is blocked by
pretreatment with an intra-PL infusion of AM251 15 minutes before the reinstatement test (n = 6, *p < .05, compared with

extinction). (C) Injection needle tips of all rats included in the intra-PL AM251 experiment. Data are presented as mean
± SEM.

Figure 4. Cannabinoid receptor type 1 (CB1R) activation in the prelimbic cortex(PL) is sufficient to potentiate
reinstatement. (A) Intra-PL administration of the CB1R agonist WIN 55,212-2 (WIN) (50 ng/0.3 μL) 15 minutes before a lowdosecocaine injection (COC) (2.5 mg/kg, intraperitoneal [i.p.]) induces significant reinstatement of cocaine-seeking behavior
while either administered alone does not (n = 6, *p < .05, compared with extinction). (B) Intra-PL administration of a
monoacylglycerol lipase inhibitor URB602 (URB) (300 pmol/0.3 μL), which elevates 2-arachidonoylglycerol levels and acts
an indirect agonist of CB1R, 60 minutes before a low-dose cocaine injection (2.5 mg/kg, i.p.) induces significant
reinstatement while administration of either alone does not (n = 6, *p < .05, compared with extinction). (C) Injection needle
tips of all rats included in the intra-PL experiment. Data are presented as mean ± SEM.

There is evidence that stress can mobilize the endocannabinoid 2-AG in the PL (16), suggesting that CB1Rdependent effects of corticosterone may be mediated through 2-AG signaling. To determine if elevated 2-AG
levels are sufficient to potentiate reinstatement, we tested rats for the effect of intra-PL administration of
URB602, an inhibitor of the enzyme monoacylglycerol lipase, which is responsible for the breakdown of 2-AG. As
was the case with corticosterone and WIN 55,212-2, neither intra-PL URB602 (300 pmol/0.3 μL; 60-minute
pretreatment) nor 2.5 mg/kg (i.p.) cocaine alone increased cocaine seeking, but significant reinstatement was
observed when URB602 preceded the cocaine injection (Figure 4B; two-way RM ANOVA, reinstatement
condition × day interaction [F2,10 = 5.89, p < .05], post hoc comparison URB602/cocaine combination vs.
extinction, p < .05). Collectively, these data demonstrate that endocannabinoid signaling in the PL is necessary
and sufficient for stress- and corticosterone-potentiated reinstatement, and suggest that corticosterone may
potentiate reinstatement through increased 2-AG signaling.

Corticosterone Potentiates Reinstatement Through Increased 2-AG Signaling in the PL

To further test if PL 2-AG signaling mediates corticosterone effects on reinstatement, DO34 (provided by the
Cravatt lab, Scripps Research Institute, La Jolla, CA), a novel inhibitor of DAGL, the synthetic enzyme for 2-AG,
was used. Bath application of DO34 (1 μM) to PL cortical slices blocked depolarization-induced suppression of
inhibition (n = 7 to 8, p < .01), which is CB1R dependent (18), suggesting that 2-AG signaling plays a critical role in
endocannabinoid effects on PL neurotransmission (Figure 5A). Furthermore, intra-PL administration of DO34 (1
μg/0.3 μL; 30-minute pretreatment) before a systemic injection of corticosterone (2 mg/kg, i.p.) significantly
reduced PL 2-AG content in a corticosterone-dependent manner (Figure 5B; two-way ANOVA with DO34 and
corticosterone treatments as between factors, main effect of DO34 [F1,26 = 6.97, p < .01], main effect of
corticosterone [F1,26 = 1.98, p > .05], DO34 × corticosterone [F1,26 = 2.09, p > .05]), while having no effect on
levels of anandamide (Supplemental Figure S2; p > .05). Confirming a role for PL 2-AG in the corticosteronedependent stress-induced potentiation of cocaine seeking, intra-PL administration of DO34 (0.1, 1 μg/0.3 μL; 30minute pretreatment) before systemic corticosterone dose-dependently inhibited the ability of stress-level
corticosterone to potentiate cocaine seeking when combined with low-dose cocaine (Figure 5C; two-way RM

ANOVA, reinstatement condition × day interaction [F4,16 = 3.84, p < .05], post hoc comparisons,
vehicle/corticosterone/cocaine combination vs. extinction, p < .05; DO34 0.1/corticosterone/cocaine or DO34
1.0/corticosterone/cocaine vs. extinction, p >.05). Taken together these data suggest that, during stress,
corticosterone-induced PL 2-AG signaling acting via CB1Rs attenuates inhibitory neurotransmission to increase
the excitability of cortical outputs mediating cocaine seeking, thereby promoting relapse vulnerability to
ordinarily subthreshold triggers.

Figure 5. Corticosterone (CORT)-potentiated reinstatement is dependent on 2-arachidonoylglycerol (2-AG) signaling in
the prelimbic cortex (PL). (A) Bath application of the diacylglycerol lipase inhibitor DO34 (1 μM) to PL slices
blocks depolarization-induced suppression of inhibition (n = 7–8, p < .01). (B) Direct administration of the diacylglycerol
lipase inhibitor DO34 (1 μg/0.3 μL) into the PL 30 minutes before a systemic injection of corticosterone (2 mg/kg,
intraperitoneal [i.p.]) attenuates PL 2-AG in the presence of corticosterone (n =7–8; *p < .05, main effect of
DO34). (C) Corticosterone-potentiated reinstatement is dose-dependently blocked by intra-PL administration of DO34 (0.1
μg/0.3 μL, 1.0 μg/0.3 μL) 30 minutes before the corticosterone injection (n = 5; *p < .05, compared with
extinction). (D) Injection needle tips of all rats included in the intra-PL experiment. Data are presented as mean ± SEM. COC,
cocaine injection; IPSC, inhibitory postsynaptic currents; Sac, sacrifice animal.

Discussion

Stress is a powerful determinant of drug seeking in individuals with SUDs. This is problematic for relapse
prevention, as stress is prevalent and unavoidable in the daily lives of drug addicts. Although the general idea
that stress contributes to drug seeking is well established 22, 23, 24, the nature of this contribution appears to
be more complex than previously thought. While it is true that in some cases, stress can serve as a direct

trigger for drug craving 2, 11, supported by findings in rodent models (11), recent evidence points to a more
opportunistic role of stress that involves interactions with other factors that promote relapse [e.g., cues, drug
re-exposure; 4, 5, 25]. Consistent with reports from individuals with SUDs, these findings imply that stress may
function by augmenting the ability of other stimuli to elicit drug seeking, thereby “setting the stage” for relapse.
We have recently established a preclinical model for these stage-setting effects of stress wherein stress can
potentiate, but not directly trigger, reinstatement of cocaine seeking in response to an otherwise subthreshold
priming injection of cocaine 8, 10. Similarly, it has been reported that stress can potentiate the reinstatement of
drug seeking upon the presentation of drug-associated cues 7, 9, 26. Importantly, evidence suggests that the
neurobiological processes that mediate stress-potentiated reinstatement are distinct from those that mediate
stress-triggered cocaine seeking. Specifically, shock-potentiated cocaine seeking, observed in rats with a history
of shorter daily access to cocaine, requires acute elevation of corticosterone (8) and CB1R activation (10), while
shock-triggered cocaine seeking, observed in rats with a history of longer daily access to cocaine, does
not 10, 26.
Here we identify the prelimbic subregion of the medial prefrontal cortex as a critical site of action for the
corticosterone-dependent stage-setting effects of stress on cocaine seeking. We demonstrate that the ability of
stress and stress-level corticosterone to potentiate cocaine-induced reinstatement is reproduced by intra-PL
corticosterone delivery. The PL has been previously implicated in drug seeking in response to multiple
reinstating stimuli 13, 14, 15 and is critical for the control of goal-directed behavior (27). Moreover, the medial
prefrontal cortex is highly responsive to stress, as it contains a high density of glucocorticoid
receptors 28, 29 and is heavily regulated by corticosterone, which acts in the region to exert negative
feedback on the hypothalamic-pituitary-adrenal axis 18, 30 and modify neuronal morphology 31, 32, gene
transcription33, 34, synaptic physiology 18, 35, 36, 37, 38, and behavior 39, 40, 41, 42.
In the PL, corticosterone likely regulates cocaine seeking through a CB1R-dependent attenuation of
GABAergic neurotransmission. Here we report that both stress- and corticosterone-potentiated reinstatement
are prevented by intra-PL administration of the CB1R antagonist AM251, while intra-PL administration of the
CB1R agonist WIN 55,212-2 is sufficient to potentiate cocaine-induced reinstatement. The PL CB1Rs are located
predominately on GABAergic interneurons (18) and activation of CB1Rs in the prefrontal cortex attenuates
inhibitory neurotransmission (43). In mice, ex vivo bath application of corticosterone to medial prefrontal cortex
slices produces a CB1R-dependent reduction in inhibitory neurotransmission (18). Furthermore, we demonstrate
that bath application of corticosterone to rat PL slices attenuates both spontaneous and evoked inhibitory
neurotransmission via a CB1R-dependent presynaptic mechanism in rats.
The effects of stress and corticosterone on reinstatement likely involve mobilization of 2-AG in the PL. Prior
studies have suggested that stress and glucocorticoids mobilize 2-AG 44, 45, particularly in the prefrontal
cortex (18). Here we report that intra-PL delivery of a monoacylglycerol lipase inhibitor, URB602, which elevates
2-AG brain content 46, 47, is sufficient to potentiate reinstatement in response to low-dose cocaine, similar to
what is observed with stress, corticosterone, and intra-PL CB1R agonist administration. However, a role
for anandamide signaling was not examined in the current study and cannot be ruled out. To determine if
corticosterone potentiates reinstatement through 2-AG mobilization, we utilized a novel DAGL inhibitor, DO34,
which reduces 2-AG brain content (48). Bath application of DO34 blocks depolarization-induced suppression of
inhibition in the PL, which is known to be CB1R dependent (18), suggesting that mobilization of 2-AG is critical for
endocannabinoid-regulated synaptic plasticity, while intra-PL DO34 both prevents corticosterone-potentiated
reinstatement and reduces PL 2-AG content in corticosterone-treated rats without altering anandamide levels.
Interestingly, while intra-PL administration of the DAGL inhibitor DO34 reduced 2-AG content in corticosteronetreated rats, a corticosterone-induced elevation of PL 2-AG was not observed, in contrast to earlier studies
demonstrating glucocorticoid-dependent stress-induced mobilization of 2-AG (16). However, these findings are

consistent with reports that systemic administration of corticosterone alone does not elevate anandamide or 2AG in the prefrontal cortex as observed with bulk tissue dissection (49). Given that a majority of brain tissue 2AG content is not involved in signaling (50), tissue concentration of 2-AG may not be sensitive to an increase in
2-AG mobilization at the synapse. The mechanism through which corticosterone regulates
PL endocannabinoid signaling is unclear and will require further investigation.
Our data suggest that corticosterone potentiates reinstatement through an endocannabinoid-mediated, likely 2AG, attenuation of inhibitory neurotransmission, which should increase the excitability of outputs mediating
drug seeking. This is supported by findings that acute stress recruits endocannabinoid signaling, specifically 2AG, to attenuate inhibitory neurotransmission in the basolateral amygdala (44). While the current study did not
directly examine specific PL projection fields, the projection pathway from the PL to the nucleus accumbens
core is one likely to be affected as it has been established as a key pathway for cocaine
seeking 13, 14, 15, 51, 52, 53. Specifically, we hypothesize that corticosterone mobilizes 2-AG, thereby activating
CB1Rs that regulate GABA release from cortical interneurons, to attenuate inhibitory regulation of corticoaccumbens pyramidal projection neurons. This disinhibition would render the cortico-accumbens pathway more
responsive to convergent PL excitatory inputs, including those activated by stimuli that trigger cocaine seeking.
This hypothesis is consistent with a previous report that attenuated GABAergic neurotransmission in the medial
prefrontal cortex facilitates cue-induced reinstatement to nicotine seeking (54). However, this requires further
study, as it is unknown whether corticosterone-potentiated reinstatement results in increased activation of the
cortico-accumbens pathway, and there are several possible PL projection pathways that can regulate
potentiated cocaine seeking. Furthermore, while CB1Rs are predominantly on GABAergic terminals in the PL, it is
not currently known whether corticosterone can potentially regulate neurotransmission in a CB1R-dependent
manner through non-GABAergic mechanisms.
While our findings demonstrate that the PL is an important site for corticosterone effects, it is not the only site
at which corticosterone can regulate cocaine seeking. This may contribute to the differential magnitude of
reinstatement observed with intraperitoneal versus intra-PL administration of corticosterone. We previously
reported that corticosterone delivery into the nucleus accumbens can also potentiate cocaine-induced
reinstatement in rats. However, the effects of corticosterone in the nucleus accumbens involve its inhibition of
organic cation transporter 3, a secondary uptake mechanism for monoamines, and the resulting decrease in
dopamine clearance (8). However, there is likely interplay between the two brain regions, and others, during
reinstatement. Furthermore, it is possible that organic cation transporter 3 and endocannabinoid mechanisms
may work in tandem within the PL itself. Ultimately, the ability of corticosterone to regulate behavior at multiple
sites suggests that during periods of stress, glucocorticoids may impose a brain state that produces system-wide
changes in synaptic transmission to promote adaptive behavioral response patterns. The ubiquitous nature of
endocannabinoid signaling suggests that glucocorticoid mobilization of 2-AG may serve as a key mechanism
through which stress shifts neuronal excitabilityand therefore influence behavior at the network level.
The complexity of the contribution of stress to drug seeking has limited our ability to develop effective strategies
for relapse prevention aimed at targeting stress-responsive mechanisms. Here we report that stress, under
conditions in which it does not directly trigger responding, can potentiate cocaine-induced reinstatement in a
rodent model, thereby setting the stage for cocaine seeking. This approach is consistent with many clinical
reports and therefore may offer greater validity for studying the contribution of stress to relapse. Importantly,
the observation that the neurobiological mechanisms underlying these “stage-setting” effects of stress are
distinct from those through which stress triggers cocaine seeking, suggests that this model has the potential to
reveal new targets for relapse prevention.
Finally, while our findings have direct implications for understanding SUDs, the ability of stress to modify
synaptic transmission and neuronal excitability in the PL via glucocorticoid regulation of endocannabinoid

signaling has important implications for a range of stress-related pathological conditions that have been
associated with prefrontal cortical dysregulation.
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Supplementary Material
Stress Promotes Drug Seeking Through Glucocorticoid-Dependent Endocannabinoid Mobilization in Prelimbic
Cortex
Supplemental Information
Supplemental Methods and Materials
Subjects: Male Sprague-Dawley rats (275-300g at arrival) obtained from Envigo (Indianapolis, IN) were
individually housed in a humidity- and temperature-controlled, AAALAC-accredited facility with ad libitum access
to food and water. Rats were housed under a 12-h/12-h reverse light/dark cycle (0700-1900 lights off). For
electrophysiology experiments, male Sprague-Dawley rats (200-250g at arrival) were obtained from Charles
River laboratories (Wilmington, MA). All behavioral procedures were completed in the dark phase of the light
cycle. All experimental procedures were carried out in compliance with National Institutes of Health Guidelines
and were approved by Institutional Animal Care and Use Committees (Marquette University and Medical College
of Wisconsin).
Surgery: For intravenous cocaine self-administration, rats were anesthetized with ketamine HCl (100 mg/kg, i.p.;
Henry Schein, Melville, NY) and xylazine (2 mg/kg, i.p.; Henry Schein, Melville, NY) and had an indwelling venous
catheter implanted surgically. The polyurethane (0.6 mm i.d. x 1.1 mm o.d.; Access Technologies, Skokie, IL)
catheters were connected to a back-mounted cannula (Plastics One, Roanoke, VA) attached to polypropylene
mesh (500 microns; Small Parts, Logansport, IN). Catheters were implanted into the superior vena cava with the
back-mount placement situated approximately 1 inch behind the scapula. For rats that received intra-prelimbic
cortical (PL) infusions prior to reinstatement testing, guide cannula were surgically implanted immediately
following catheter surgery. For guide cannula implantation, the skull was positioned n a stereotaxic frame
(Stoelting Inc; Wood Dale, IL) and two 11-mm stainless steel guide cannula (26 gauge; Plastics One, Roanoke,
VA) were positioned 0.5 mm above the PL [coordinates (in mm): anteroposterior (A/P): +2.8 from Bregma;
mediolateral (M/L): +1.0 from midline; dorsoventral (D/V): -3.5 from the skull surface; incisor bar: -3.3 from
interaural line (Paxinos and Watson, 2005)]. Guide cannula were fixed in place with acrylic dental cement and
four small anchoring screws. Internal dummy cannula were inserted into each cannula to maintain patency. Rats
were given Bio-Serv Rimadyl tablets (5 g; Fisher Scientific; Hampton, NH) in their cage for 3 days and antibiotic
treatment (100 mg/kg, iv; Cefazolin; Henry Schein, Melville, NY) for at least 5 days following surgery. All rats
recovered for a minimum of one week before the initiation of self-administration.
Cocaine self-administration, extinction, and reinstatement: Self-administration procedures were conducted in
computer-interfaced operant conditioning chambers equipped with retractable levers and stimulus lights above

each lever in sound-attenuating cubicles (MED-Associates; Fairfax, VT). Following recovery from surgery, rats
were food deprived to 90% of their body weight and were then trained to receive sucrose pellets by pressing a
lever under a fixed-ratio (FR) 1 schedule. Once rats successfully acquired lever pressing for food, rats were then
switched over to self- administer cocaine (0.5 mg/kg/infusion) by pressing a lever under a FR1 schedule during
daily 2- h sessions. Pressing the lever resulted in an infusion (200 μL over 5-sec) followed by a 10-sec time-out
period, during which lever presses were recorded but not reinforced and the stimulus light above the lever was
extinguished and the house light turned on. Responding on a second, inactive lever was also recorded but not
reinforced. Following stable responding, the FR value was increased gradually to FR4. Once stable responding on
FR4 was maintained (<10% change over 3 days), rats were provided access to cocaine for self-administration
during daily 2-h sessions for 14 days. Rats then underwent extinction training, wherein the cocaine syringe was
replaced with saline, until the extinction criterion was met (<10 lever presses/2 h). Once rats met this criterion, a
reinstatement test was conducted the following day.
Reinstatement conditions: The 2-h reinstatement tests were preceded by footshock, corticosterone, and cocaine
and/or drug delivery but were otherwise identical to extinction conditions. A complete within-subjects design
was used wherein all rats underwent multiple reinstatement tests within each experiment in a counterbalanced
fashion for a maximum of 6 reinstatement tests. Rats that did not complete all reinstatement tests were
excluded from analysis. Rats were given additional extinction/washout sessions between reinstatement tests to
reestablish extinction criterion (<10 lever presses/2 h) before receiving additional tests. For stress-potentiated
reinstatement of cocaine seeking, the electric footshock stress (3 x 0.5 mA, 200-msec duration, mean intershock
interval 40-sec, range 10-70-sec over a 15-min period) was administered through stainless steel grid floors.
Immediately following cessation of the electric footshock stress, a subthreshold dose of cocaine (2.5 mg/kg, i.p.)
or saline was given followed by the 2-h reinstatement session. For corticosterone- potentiated reinstatement of
cocaine seeking, a systemic injection of corticosterone (2 mg/kg, i.p) or vehicle (10% EtOH) was administered 40min prior to an injection of low-dose cocaine (2.5 mg/kg, i.p) or saline, followed by the 2-h reinstatement
session.
Intra-cranial drug administration: HBC-conjugated corticosterone (50 ng/0.3 µL; Sigma-Aldrich, St. Louis, MO),
the CB1R antagonist AM251 (300 ng/0.3 µL; Sigma-Aldrich, St. Louis, MO), the CB1R agonist WIN 55,212-2 (50
ng/0.3 µL; Sigma-Aldrich, St. Louis, MO), the MAGL inhibitor URB602 (300 pmol/0.3 µL; Tocris, Bristol UK), or the
DAGL inhibitor DO34 (0.1, 1.0 µg/0.3 µL; Cravatt Lab, Scripps Research Institute) were micro-infused directly into
the PL at various times prior to reinstatement testing as described in the Results section. Infusion needles were
comprised of 11.5 mm 30-gauge stainless steel injectors (Plastics One, Roanoke, VA) attached to polyethylene20 tubing and Hamilton syringes. The vehicle or drug was backfilled into the infusion needle and all drugs were
infused at a volume of 0.3 µL and at a rate of 0.3 µL/min using a syringe pump. The needles remained in place
for an additional 1-min to allow for diffusion.
Trunk blood collection and plasma corticosterone analysis: To confirm that the systemic dose of corticosterone
used in the study recapitulates stress-evoked increases in blood levels of corticosterone, plasma corticosterone
levels were quantified by radioimmunoassay (RIA) following either electric footshock stress or systemic
corticosterone administration. Some rats received the same 15-min intermittent electric footshock stress
parameters used for behavioral testing, and were sacrificed immediately after cessation of the footshock. Other
rats were assigned to a No Shock control wherein rats were placed in the self-administration chamber for 15 min
and were sacrificed immediately afterward. Another group of rats were given a systemic injection of
corticosterone (2 mg/kg, i.p.) or vehicle (10% EtOH) and were sacrificed 40-min after the injection. All animals
were sacrificed by rapid decapitation, and trunk blood collected for analysis. Trunk blood was collected into
centrifuge tubes containing heparin and the blood was spun in a centrifuge at 1000 x g for 10-min to separate
the plasma. The plasma was transferred into a new tube and stored at −80°C for long-term storage.

Corticosterone levels in plasma were determined by using a 3H-Corticosterone RIA kit (MP Biomedicals, Santa
Ana, CA) according to the manufacturer protocol.
Slice electrophysiology: Drug-naïve rats were anaesthetized by isoflurane inhalation and decapitated. Cortical
slices were cut using a vibrating slicer (Leica, Wetzler, Germany). The slices were transferred into artificial
cerebrospinal fluid (ACSF) containing (in mM): 119 NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 NaHCO3,
and 10 glucose, and allowed to recover at least one hour at room temperature. All solutions were saturated with
95% O2 and 5% CO2. Whole-cell voltage clamp recordings were made using a patch clamp amplifier (Multiclamp
700B; Molecular Devices, Sunnyvale, CA) under infrared-differential contrast interference microscopy. Data
acquisition and analysis were performed using a digitizer (DigiData 1440A; Molecular Devices, Sunnyvale, CA)
and analysis software pClamp 10 (Molecular Devices, Sunnyvale, CA). Pyramidal neurons in layer V of the PL
were identified visually based upon pyramidal-shaped soma with a prominent apical dendrite. Additionally, the
pyramidal neurons exhibit spike frequency adaptation in response to depolarizing current injections (1). For
recording of evoked IPSCs, layer V pyramidal neurons were voltage-clamped at −60 mV, and IPSCs were evoked
at 0.05 Hz by a tungsten stimulation electrode placed near the apical dendrites. The pipettes were filled with an
internal solution containing (in mM): 80 K-gluconate, 60 KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 2 Mg-ATP, 0.3
Na2GTP, and 10 Na2-phosphocreatine (pH 7.2 with KOH). Spontaneous miniature IPSCs (mIPSCs) were recorded
from pyramidal neurons at a holding potential of −70 mV. Action potential generation was blocked with
tetrodotoxin (TTX; 0.5 μM). Glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10
µM) and D-2-amino-5-phosphonovaleric acid (D-AP-5, 20 µM) were present in the ACSF throughout the
experiments. Series resistance (15-30 MΩ) was monitored throughout the recordings, and data were discarded
if the resistance changed by more than 20%. All recordings were performed at 32 ± 1°C by using an automatic
temperature controller.
Mass spectrometry: To assess effects of the DAGL inhibitor DO34 on corticosterone-induced 2arachidonoylglycerol (2-AG) content, rats received intra-PL infusions of DO34 (1 µg/0.3µL) or vehicle (70%
DMSO) 30 min prior to a corticosterone (2 mg/kg, ip) or vehicle (10% EtOH) injection. Rats were rapidly
decapitated 45-min following the injection and brains were removed and flash frozen by submersion in liquid
nitrogen (total time from decapitation was approximately 90-sec) and stored at −80°C. For tissue dissection, 1
mm prelimbic prefrontal cortical sections (approx. 3.72 mm to – 2.76 mm from Bregma) were isolated from
coronal sections on dry ice as described previously (2) and stored at −80°C. Placement of guide cannula was
visually confirmed to be in the prelimbic cortex during dissection. Tissue samples were weighed and
homogenized in acetonitrile containing 67 pmol [2H8]AEA and 8 nmol [2H8]2-AG (Cayman Chemical Company,
Ann Arbor, MI), sonicated for 60 min, and frozen overnight at −20°C to precipitate proteins. Particulates were
then removed by centrifugation at 1500 x g for 2 minutes at 4°C, after which the supernatant was rapidly
extracted and concentrated under N2 gas re-suspended in 100% methanol and AEA and 2-AG were isolated and
quantified by tandem liquid chromatography-mass spectrometry (LC/MS/MS; Agilent Technologies 6460 Triple
Quad LC/MS), and concentrations were calculated by isotope dilution as previously described (3).
Histology: To determine the accuracy of guide cannula placements, rats were sacrificed and brains were postfixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, and finally 50 µm sections were taken from the
level of the prelimbic cortex using a cryostat. Tissue sections were mounted onto gelatin-coated slides and
stained using a cresyl violet nuclear stain. Guide cannula placement was determined to be accurate if the
injection needle terminated in the prelimbic region of the medial prefrontal cortex. A limited number of rats
(n=5) did not have bilateral hits for cannula placement and were excluded from the study. In each case, drug
effects were not observed in rats that had injections outside of the prelimbic cortex.
Drugs: Cocaine HCl was obtained from the National Institute on Drug Abuse (NIDA) through the NIDA Drug
Supply Program. Cocaine was dissolved in saline (0.9% bacteriostatic saline). Corticosterone (Steroloids,

Newport, RI) was dissolved in a 10% EtOH in saline solution, and 2- hydroxypropyl-β-cyclodextrin (HBC)conjugated corticosterone (Sigma-Aldrich, St. Louis, MO) was dissolved in saline. AM251 (Sigma-Aldrich, St.
Louis, MO), WIN-55,212 (Tocris, Bristol, UK), URB502 (Tocris, Bristol, UK), and DO34 (0.1 µg) were made in a
vehicle containing 10% DMSO in saline. DO34 (1 µg) was made in a vehicle containing 70% DMSO in saline.
Statistical analysis: Statistical analyses were conducted using SPSS (IBM Analytics, Armonk, NY) or Sigmaplot
(Systat Software, San Jose, CA) statistics software. For behavioral experiments, lever responding was analyzed
using two-way repeated measures ANOVA followed by post-hoc testing using Bonferroni-corrected t-tests. For
electrophysiology experiments, IPSC amplitude was normalized to the baseline. The depression (%) of IPSCs by
corticosterone was calculated as follows: 100 × [mean amplitude of IPSCs during the last 5 min treatment/mean
amplitude of baseline IPSCs]. Data sets were compared with Student's t-test. For mass spectrometry,
endocannabinoid content was analyzed using a two-way ANOVA followed by post-hoc testing. For all analyses,
statistical significance was defined as p<.05.
Supplemental Data
Table S1. Cocaine self-administration and extinction responding. Data represent total active lever responses/2-h
session for Figures 1, 3, 4 and 5 during days 1 and 14 of cocaine self-administration (SA) and total active lever
responses/2-h session on the first day of extinction (Ext) and the last day of extinction before reinstatement
testing for experiments 1 and 2. The number of days to reach extinction criteria for each experiment is also
reported. Data are represented as mean ± SEM. (EFS, Electric footshock stress; COC, cocaine; CORT,
corticosterone; PL, prelimbic cortex; AM251, CB1R antagonist; WIN, WIN 55,212-2 CB1R agonist; URB602,
monoacylglycerol lipase inhibitor; DO34; diacylglycerol lipase inhibitor).
Cocaine SA
Experiment no.
(n)
1 EFS/COC; (6)
1 CORT/COC; (5)
1 PL CORT/
COC; (7)
3 PL AM251/
EFS/COC; (6)
3 PL AM251/
CORT/COC; (6)
4 PL WIN/
COC; (6)
4 PL URB602/
COC (6)
5 PL DO34/
CORT/COC (5)

Extinction

SA Day 1

SA Day 14

First Ext

Last Ext

106.00 ±
8.10
121.40 ±
10.18
115.86 ±
10.98
123.67 ±
8.38
131.00 ±
15.18
146.33 ±
17.95
112.67 ±
8.46
112.60 ±
11.44

123.83 ±
7.48
114.00 ±
13.57
137.71 ±
24.25
128.33 ±
6.95
132.50 ±
14.32
149.50 ±
28.00
117.33 ±
6.45
122.60 ±
18.99

68.50 ±
13.57
33.2 ±
13.35
68.85 ±
7.53
76.00 ±
19.24
71.83 ±
12.59
68.50 ±
10.13
77.67 ±
15.08
32.00 ±
12.41

8.67 ±
1.43
6.80 ±
1.56
7.57 ±
1.57
7.17 ±
1.49
8.83 ±
1.54
5.17 ±
2.52
8.17 ±
1.72
5.00 ±
1.58

Range of
Days to Ext
# Days

Average Days
to Ext
# Days

5-10

8.00 ± 0.85

5-15

8.80 ± 1.69

5-17

8.28 ± 1.76

4-12

7.17 ± 1.19

5-20

8.83 ± 2.30

5-9

6.67 ± 0.56

3-9

6.17 ± 0.98

5-13

9.00 ± 1.52

Table S2. Detailed statistics for experiments depicted in Figure 1. Two-way repeated measures (RM) ANOVAs
were conducted with reinstatement condition and day (extinction, reinstatement) as factors. These were
followed by separate one-way RM ANOVAs examining responding during extinction and reinstatement testing.

Post-hoc testing was conducted using Bonferroni-corrected t- tests. * denotes significance. (Ext=extinction;
Rst=reinstatement; Coc=cocaine, Cort=corticosterone; Sal=saline; Veh=vehicle).
Figure 1A
2-way RM ANOVA
Condition
Day
Condition X Day

F(3,15)=18.05, p<.001*
F(1,5)=29.59, p<.01*
F(3,15)=17.11, p<.001*

1-way RM ANOVA
Extinction
Reinstatement
Figure 1B
2-way RM ANOVA
Condition
Day
Condition X Day

F(3,15)=.05, p>.05
F(3,15)=19.26, p<.001*

F(3,12)=7.38, p<.01*
F(1,4)=5.50, p=.07
F(3,12)=10.30, p<.001*

1-way RM ANOVA
Extinction
Reinstatement
Figure 1C
2-way RM ANOVA
Condition
Day
Condition X Day
1-way RM ANOVA
Extinction
Reinstatement

F(3,12)=.55, p>.05
F(3,12)=9.07, p<.01*

F(2,12)=3.99, p<.05*
F(1,6)=6.78, p<.05*
F(2,12)=4.89, p<.05*

F(2,12)=1.01, p>.05
F(2,12)=4.80, p<.05*

Post hoc test: Ext vs Rst
No Shock/Sal
Shock/Sal
No Shock/Coc
Shock/Coc
Post hoc test: Rst –
Shock/Coc vs
No Shock/Sal
Shock/Sal
No Shock/Coc
Post hoc test: Ext vs Rst
Veh/Sal
Cort/Sal
Veh/Coc
Cort/Coc
Post hoc test: Rst –
Cort/Coc vs
Veh/Sal
Cort/Sal
Veh/Coc
Post hoc test: Ext vs Rst
Cort/Sal
Veh/Coc
Cort/Coc
Post hoc test: Rst –
Cort/Coc vs
Cort/Sal
Veh/Coc

p>.05
p>.05
p<.05*
p<.01*

p=.06
p<.05*
p<.05*

p>.05
p>.05
p>.05
p<.05*

p>.05
p>.05
p>.05

p>.05
p>.05
p<.05*

p>.05
p>.05

Table S3. Detailed statistics for experiments depicted in Figure 3. Two-way repeated measures (RM) ANOVAs
were conducted with reinstatement condition and day (extinction, reinstatement) as factors. These were
followed by separate one-way RM ANOVAs examining responding during extinction and reinstatement testing.
Post-hoc testing was conducted using Bonferroni-corrected t- tests. * denotes significance. (Ext=extinction;
Rst=reinstatement; Coc=cocaine, Cort=corticosterone; Sal=saline; Veh=vehicle).
Figure 3A
2-way RM ANOVA
Condition
Day
Condition X Day

F(3,15)=10.64, p<.001*
F(1,5)=8.80, p<.05*
F(3,15)=15.71, p<.001*

1-way RM ANOVA
Extinction

F(3,15)=.61, p>.05

Post hoc test: Ext vs Rst
Veh/Shock/Sal
Veh/No Shock/Coc
Veh/Shock/Coc
AM251/Shock/Coc
Post hoc test: Rst –
Veh/Shock/Coc vs
Veh/Shock/Sal

p>.05
p>.05
p<.01*
p>.05

p<.05*

Reinstatement

F(3,15)=19.26, p<.001*

Figure 3B
2-way RM ANOVA
Condition
Day
Condition X Day

F(3,15)=9.52, p<.001*
F(1,5)=11.14, p<.05*
F(3,15)=6.94, p<.01*

1-way RM ANOVA
Extinction
Reinstatement

F(3,15)=1.41, p>.05
F(3,15)=14.39, p<.001*

Veh/No Shock/Coc
AM251/Shock/Coc
Post hoc test: Ext vs Rst
Veh/Cort/Sal
Veh/Veh/Coc
Veh/Cort/Coc
AM251/Cort/Coc
Post hoc test: Rst –
Veh/Cort/Coc vs
Veh/Cort/Sal
Veh/Veh/Coc
AM251/Cort/Coc

p<.05*
p=.06

p>.05
p>.05
p<.05*
p>.05

p>.05
p>.05
p>.05

Table S4. Detailed statistics for experiments depicted in Figure 4. Two-way repeated measures (RM) ANOVAs
were conducted with reinstatement condition and day (extinction, reinstatement) as factors. These were
followed by separate one-way RM ANOVAs examining responding during extinction and reinstatement testing.
Post-hoc testing was conducted using Bonferroni-corrected t- tests. * denotes significance. (Ext=extinction;
Rst=reinstatement; Coc=cocaine; Sal=saline; Veh=vehicle; WIN=WIN 55,212-2).
Figure 4A
2-way RM ANOVA
Condition
Day
Condition X Day
1-way RM ANOVA
Extinction
Reinstatement
Figure 4B
2-way RM ANOVA
Condition
Day
Condition X Day
1-way RM ANOVA
Extinction
Reinstatement

F(2,10)=4.01, p<.05*
F(1,5)=6.24, p<.05*
F(2,10)=7.09, p<.01*
F(2,10)=0.18, p>.05
F(2,10)=5.39, p<.05*

F(2,10)=5.26, p<.05*
F(1,5)=8.12, p<.05*
F(2,10)=5.89, p<.05*

F(2,10)=2.94, p>.05
F(2,10)=7.47, p<.01*

Post hoc test: Ext vs Rst
WIN/Sal
Veh/Coc
WIN/Coc
Post hoc test: Rst – WIN/Coc vs
WIN/Sal
Veh/ Coc
Post hoc test: Ext vs Rst
URB602/Sal
Veh/Coc
URB602/Coc
Post hoc test: Rst – URB602/Coc
vs
URB602/Sal
Veh/Coc

p>.05
p>.05
p<.05*
p>.05
p>.05

p>.05
p>.05
p<.05*

p>.05
P<.01*

Table S5. Detailed statistics for experiments depicted in Figure 5. Two-way repeated measures (RM) ANOVAs
were conducted with reinstatement condition and day (extinction, reinstatement) as factors. These were
followed by separate one-way RM ANOVAs examining responding during extinction and reinstatement testing.
Post-hoc testing was conducted using Bonferroni-corrected t- tests. * denotes significance. (Ext=extinction;
Rst=reinstatement; Coc=cocaine; Sal=saline; Veh=vehicle; DO=DO34).
Figure 5C
2-way RM ANOVA
Condition
Day
Condition X Day

F(4,16)=5.28, p<.01*
F(1,4)=7.24, p<.05*
F(3,16)=3.84, p<.05*

Post hoc test: Ext vs Rst
Veh/Cort/Sal
Veh/Veh/Coc
Veh/Cort/Coc

p>.05
p>.05
p<.05*

1-way RM ANOVA
Extinction
Reinstatement

F(4,16)=2.11, p>.05
F(4,16)=4.62, p<.01*

DO(0.1)/Cort/Coc
DO(1.0)/Cort/Coc
Post hoc test: Rst –
Veh/Cort/Coc vs
Veh/Cort/Sal
Veh/Veh/Coc
DO(0.1)/Cort/Coc
DO(1.0)/Cort/Coc

p>.05
p>.05

p>.05
p>.05
p>.05
p>.05

Supplemental Figure S1. Plasma levels of corticosterone following footshock or systemic corticosterone
administration. A) Timeline of blood collection. Time points were selected to correspond to the start of the
reinstatement session in rats tested for behavior. B) 15-min of electric footshock stress (Shock) significantly
increases plasma levels of corticosterone (n=7-8, **p<.01 compared to No Shock). Systemic administration of
corticosterone (n=5-11, 2 mg/kg, i.p.) significantly increases plasma levels of corticosterone similar to levels
observed with footshock (** p<.01, compared to Vehicle). Data are represented as mean ± SEM.

Supplementary Figure S2. Direct administration of the diacylglycerol lipase inhibitor DO34 (1 µg/0.3 µL) into the
prelimbic cortex (PL) 30-min prior to a systemic injection of corticosterone (CORT; 2 mg/kg, i.p) has no effect on
PL anandamide (AEA) content (n=7-8, p>.05).

Supplementary Figure S3. Inactive lever responding during extinction and reinstatement tests. There was no
significant effect of reinstatement condition on lever responding under any condition. A) Inactive lever
responding corresponding to Fig 1A. B) Inactive lever responding corresponding to Fig 1B. C) Inactive lever
responding corresponding to Fig 1C. D) Inactive lever responding corresponding to Fig 3A. E) Inactive lever
responding corresponding to Fig 3B. F) Inactive lever responding corresponding to Fig 4A. G) Inactive lever
responding corresponding to Fig 4B. H) Inactive lever responding corresponding to Fig 5C. (COC, cocaine; CORT,
corticosterone; PL, prelimbic cortex; AM251, CB1R antagonist; WIN, WIN 55,212-2 CB1R agonist; URB602,
monoacylglycerol lipase inhibitor; DO34; diacylglycerol lipase inhibitor).
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